Anika to Highlight Regenerative Medicine & Orthobiologics Portfolio at 2019 Asia Pacific Orthopaedic Association Sports Meeting
04 April 2019 - 7:05AM
Business Wire
Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated
orthopedic and regenerative medicines company specializing in
therapeutics based on its proprietary hyaluronic acid ("HA")
technology, today announced plans to showcase its regenerative
medicine and orthobiologics portfolio at the 2019 Asia Pacific
Orthopaedic Association (APOA) Sports Meeting. The global meeting,
being held in Kuala Lumpur, Malaysia on April 4 – 6, will feature
an educational symposium and hands-on simulated demonstrations on
HYALOFAST, an HA-based scaffold for cartilage repair and
regeneration, which anchors Anika’s regenerative medicine
portfolio. In addition, Anika will also highlight its
viscosupplement portfolio, which includes CINGAL and MONOVISC, at
its booth #G02. The annual APOA Sports Meeting, which focuses on
sports injuries, features live cadaveric demonstrations, live
surgeries, workshops, and Meet the Expert sessions by distinguished
global thought-leaders.
“Orthopedic sports medicine and sports-related injuries are an
important focus for us given our extensive portfolio of treatments
to address the continuum of orthopedic care from managing joint
pain related to everyday and sports-related wear and tear to
repairing cartilage defects,” said Joseph Darling, President and
Chief Executive Officer of Anika Therapeutics. “We’re looking
forward to presenting new clinical evidence and technical tips on
the use of HYALOFAST at the APOA Sports Meeting to demonstrate the
ease of use and clinical benefits of the minimally-invasive,
one-step cartilage regeneration procedure to orthopedic surgeons
from around the world.”
“As part of my clinical research, I have been using HYALOFAST
for over eight years to treat cartilage lesions,” said Prof. Mahmut
Nedim Doral, MD, APOA President and Chairman of the Department of
Orthopaedics and Traumatology at UFUK University. “Clinical results
utilizing HYALOFAST to repair cartilage in the ankle have been very
satisfying for both myself and the many patients I treated. I am
excited to be sharing my surgical techniques and results during
Anika’s symposium at the APOA Sports Meeting 2019 in Kuala
Lumpur.”
Below are the Anika-sponsored activities being held at the 2019
APOA Sports Meeting:
SYMPOSIUM: HYALOFAST One-Step Procedure in Cartilage Repair:
Path-Breaking, Interactive SymposiumFriday, April 5, 201912:15
– 12:45pmHilton Kuala Lumpur – Lecture Hall BModerator: Prof.
Mahmut Nedim Doral, MD, APOA President and Chairman of the
Department of Orthopaedics and Traumatology at UFUK University in
Ankara, TurkeyTopics/Speakers:
- HYALOFAST plus microfracture for
cartilage repair in the knee: 3-year results and surgical tips
& tricksDr. Tho Kam San, orthopedic surgeon at Gleneagles
Hospital in Singapore
- HYALOFAST in the treatment of
osteochondral lesion of the ankle: surgical technique and clinical
resultsProf. Mahmut Nedim Doral
Anika Exhibit Booth #G02
- Featuring the HYALOFAST arthroscopic
virtual simulator for demonstrations on surgical application
About HYALOFAST
HYALOFAST is a non-woven, single-step, off-the-shelf,
biodegradable HA-based scaffold for hyaline-like cartilage
regeneration to treat cartilage injuries and defects. HYALOFAST is
commercially available in approximately 15 countries and has been
used to successfully treat approximately 16,000 patients
internationally, and with strong eight-year patient follow-up data.
HYALOFAST is pending regulatory submission in the United States and
its FastTRACK Phase III trial is currently enrolling patients
across the U.S. and Europe.
About Anika Therapeutics, Inc.
Anika Therapeutics, Inc. (NASDAQ: ANIK) is a global,
integrated orthopedic and regenerative medicines company based
in Bedford, Massachusetts. Anika is committed to improving the
lives of patients with degenerative orthopedic diseases and
traumatic conditions with clinically meaningful therapies along the
continuum of care, from palliative pain management to regenerative
tissue repair. The Company has over two decades of global expertise
developing, manufacturing, and commercializing more than 20
products based on its proprietary hyaluronic acid (HA)
technology. Anika's orthopedic medicine portfolio
includes ORTHOVISC®, MONOVISC®,
and CINGAL®, which alleviate pain and restore
joint function by replenishing depleted HA,
and HYALOFAST, a solid HA-based scaffold to aid
cartilage repair and regeneration. For more information about
Anika, please visit www.anikatherapeutics.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190403005714/en/
For Investor Inquiries:Anika Therapeutics, Inc.Sylvia Cheung,
781-457-9000Chief Financial Officer
For Media Inquiries:W2O GroupSonal Vasudev,
917-523-1418sonal@w2ogroup.com
Anika Therapeutics (NASDAQ:ANIK)
Historical Stock Chart
From Apr 2024 to May 2024
Anika Therapeutics (NASDAQ:ANIK)
Historical Stock Chart
From May 2023 to May 2024